US 12,201,115 B2
Anti-pathogen compositions
Jeffery L. Dudding, Center, MO (US); and Amod P. Paranjpe, Augusta, MO (US)
Assigned to CLAW Biotech Holdings, LLC, St. Louis, MO (US)
Appl. No. 17/638,368
Filed by CLAW Biotech Holdings, LLC, St. Louis, MO (US)
PCT Filed Aug. 25, 2020, PCT No. PCT/US2020/047841
§ 371(c)(1), (2) Date Feb. 25, 2022,
PCT Pub. No. WO2021/041439, PCT Pub. Date Mar. 4, 2021.
Claims priority of provisional application 63/007,743, filed on Apr. 9, 2020.
Claims priority of provisional application 62/893,513, filed on Aug. 29, 2019.
Prior Publication US 2022/0322677 A1, Oct. 13, 2022
Int. Cl. A61K 9/14 (2006.01); A01N 25/10 (2006.01); A01N 25/12 (2006.01); A01N 25/34 (2006.01); A01N 59/16 (2006.01); A01N 59/20 (2006.01); A01P 1/00 (2006.01); A61K 8/19 (2006.01); A61K 8/27 (2006.01); A61Q 17/00 (2006.01)
CPC A01N 59/20 (2013.01) [A01N 25/10 (2013.01); A01N 25/12 (2013.01); A01N 25/34 (2013.01); A01N 59/16 (2013.01); A01P 1/00 (2021.08); A61K 8/19 (2013.01); A61K 8/27 (2013.01); A61Q 17/005 (2013.01)] 8 Claims
 
1. An anti-pathogen solid composition comprising about 0.01% to about 5% by weight of an active component, wherein the active component comprises particles of an activated transition metal oxide; and
about 1% to about 99.99% by weight of a polymer, wherein:
the activated transition metal oxide comprises MoO2, MoO3, H2MoO5, MoO6, or a hydrate thereof;
the particles of the activated transition metal oxide have a cubic, spherical, monoclinic, hexagonal, orthorhombic, tetragonal, triclinic, or rhombohedral crystal structure;
the particles of the activated transition metal oxide have a size of between larger than 100 nm and smaller than 100 μm; and
the polymer is polypropylene.